CD19 and acute lymphoblastic leukemia: Within a CD19 CAR-T cell phase 1 dose-escalation trial for ALL patients, significantly higher levels of C-reactive protein (CRP) were seen in patients who had severe CRS compared to those with mild or no CRS [147].